Galapagos NV is a biopharmaceutical company that discovers and develops innovative medicines for high unmet medical needs. Its product pipeline includes treatments for rheumatoid arthritis, Crohn's disease, ulcerative colitis, osteoarthritis, inflammation, idiopathic pulmonary fibrosis, cystic fibrosis, and polycystic kidney disease. The company has collaboration agreements with Gilead Sciences, AbbVie, and Novartis, and is based in Mechelen, Belgium.